Does the media favor KIDS or BFLY?

In the previous week, Butterfly Network had 6 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for Butterfly Network and 7 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.75 beat Butterfly Network's score of 0.54 indicating that OrthoPediatrics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Butterfly Network 6 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ATRC or KIDS?

AtriCure has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 4.22 -$11.45M $0.21 210.95 OrthoPediatrics $236.35M 2.74 -$39.65M -$1.68 N/A

Does the media prefer ATRC or KIDS?

In the previous week, OrthoPediatrics had 1 more articles in the media than AtriCure. MarketBeat recorded 7 mentions for OrthoPediatrics and 6 mentions for AtriCure. AtriCure's average media sentiment score of 0.80 beat OrthoPediatrics' score of 0.75 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KIDS or ENOV more profitable?

OrthoPediatrics has a net margin of -15.72% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat OrthoPediatrics' return on equity. Company Net Margins Return on Equity Return on Assets OrthoPediatrics -15.72% -8.10% -5.54% Enovis -47.96% 12.03% 4.91%

Does the media favor KIDS or ENOV?

In the previous week, Enovis had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 8 mentions for Enovis and 7 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.75 beat Enovis' score of 0.23 indicating that OrthoPediatrics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KIDS or NVCR?

In the previous week, OrthoPediatrics had 2 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for OrthoPediatrics and 5 mentions for NovoCure. NovoCure's average media sentiment score of 1.42 beat OrthoPediatrics' score of 0.75 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OMCL or KIDS?

In the previous week, OrthoPediatrics had 4 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for OrthoPediatrics and 3 mentions for Omnicell. Omnicell's average media sentiment score of 1.19 beat OrthoPediatrics' score of 0.75 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OrthoPediatrics (KIDS) Competitors

$24.80 -0.21 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$24.82 +0.02 (+0.08%)

As of 07:34 PM Eastern

Compare

KIDS vs. BFLY, ATRC, ENOV, NVCR, and OMCL

Should you buy OrthoPediatrics stock or one of its competitors? OrthoPediatrics's main competitors and comparable companies include Butterfly Network (BFLY), AtriCure (ATRC), Enovis (ENOV), NovoCure (NVCR), and Omnicell (OMCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does OrthoPediatrics compare to Butterfly Network?

OrthoPediatrics (NASDAQ:KIDS) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

OrthoPediatrics currently has a consensus target price of $25.89, indicating a potential upside of 4.39%. Butterfly Network has a consensus target price of $5.56, indicating a potential downside of 37.19%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts plainly believe OrthoPediatrics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Butterfly Network had 6 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for Butterfly Network and 7 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.75 beat Butterfly Network's score of 0.54 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Butterfly Network	6 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OrthoPediatrics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

OrthoPediatrics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.74	-$39.65M	-$1.68	N/A
Butterfly Network	$97.61M	24.16	-$77.06M	-$0.29	N/A

OrthoPediatrics has a net margin of -15.72% compared to Butterfly Network's net margin of -66.74%. OrthoPediatrics' return on equity of -8.10% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
Butterfly Network	-66.74%	-33.99%	-22.96%

Summary

OrthoPediatrics beats Butterfly Network on 12 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to AtriCure?

AtriCure (NASDAQ:ATRC) and OrthoPediatrics (NASDAQ:KIDS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

AtriCure currently has a consensus price target of $48.50, indicating a potential upside of 9.48%. OrthoPediatrics has a consensus price target of $25.89, indicating a potential upside of 4.39%. Given AtriCure's stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 32.5% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

AtriCure has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, OrthoPediatrics had 1 more articles in the media than AtriCure. MarketBeat recorded 7 mentions for OrthoPediatrics and 6 mentions for AtriCure. AtriCure's average media sentiment score of 0.80 beat OrthoPediatrics' score of 0.75 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a net margin of 1.85% compared to OrthoPediatrics' net margin of -15.72%. AtriCure's return on equity of 2.34% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
OrthoPediatrics	-15.72%	-8.10%	-5.54%

AtriCure has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	4.22	-$11.45M	$0.21	210.95
OrthoPediatrics	$236.35M	2.74	-$39.65M	-$1.68	N/A

Summary

AtriCure beats OrthoPediatrics on 14 of the 17 factors compared between the two stocks.

How does OrthoPediatrics compare to Enovis?

OrthoPediatrics (NASDAQ:KIDS) and Enovis (NYSE:ENOV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

OrthoPediatrics has a net margin of -15.72% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
Enovis	-47.96%	12.03%	4.91%

OrthoPediatrics currently has a consensus target price of $25.89, indicating a potential upside of 4.39%. Enovis has a consensus target price of $42.00, indicating a potential upside of 61.02%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

OrthoPediatrics has higher earnings, but lower revenue than Enovis. OrthoPediatrics is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.74	-$39.65M	-$1.68	N/A
Enovis	$2.25B	0.67	-$1.18B	-$19.26	N/A

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

OrthoPediatrics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Enovis has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

In the previous week, Enovis had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 8 mentions for Enovis and 7 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.75 beat Enovis' score of 0.23 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

OrthoPediatrics and Enovis tied by winning 8 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to NovoCure?

OrthoPediatrics (NASDAQ:KIDS) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, OrthoPediatrics had 2 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for OrthoPediatrics and 5 mentions for NovoCure. NovoCure's average media sentiment score of 1.42 beat OrthoPediatrics' score of 0.75 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 32.5% of OrthoPediatrics shares are held by insiders. Comparatively, 6.6% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OrthoPediatrics has higher earnings, but lower revenue than NovoCure. OrthoPediatrics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$236.35M	2.74	-$39.65M	-$1.68	N/A
NovoCure	$655.35M	3.01	-$136.23M	-$1.30	N/A

OrthoPediatrics has a net margin of -15.72% compared to NovoCure's net margin of -21.25%. OrthoPediatrics' return on equity of -8.10% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
NovoCure	-21.25%	-44.00%	-15.85%

OrthoPediatrics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

OrthoPediatrics currently has a consensus price target of $25.89, indicating a potential upside of 4.39%. NovoCure has a consensus price target of $21.20, indicating a potential upside of 25.07%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

OrthoPediatrics beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to Omnicell?

Omnicell (NASDAQ:OMCL) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Omnicell has a net margin of 3.13% compared to OrthoPediatrics' net margin of -15.72%. Omnicell's return on equity of 5.66% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
OrthoPediatrics	-15.72%	-8.10%	-5.54%

Omnicell currently has a consensus price target of $57.86, suggesting a potential upside of 55.11%. OrthoPediatrics has a consensus price target of $25.89, suggesting a potential upside of 4.39%. Given Omnicell's higher probable upside, equities analysts clearly believe Omnicell is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, OrthoPediatrics had 4 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for OrthoPediatrics and 3 mentions for Omnicell. Omnicell's average media sentiment score of 1.19 beat OrthoPediatrics' score of 0.75 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 32.5% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omnicell has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Omnicell has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.43	$2.05M	$0.84	44.40
OrthoPediatrics	$236.35M	2.74	-$39.65M	-$1.68	N/A

Summary

Omnicell beats OrthoPediatrics on 10 of the 15 factors compared between the two stocks.

Get OrthoPediatrics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KIDS vs. The Competition

Export

Metric	OrthoPediatrics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$653.01M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-14.76	26.22	269.06	25.28
Price / Sales	2.74	63.09	602.43	91.76
Price / Cash	150.40	33.92	70.48	50.90
Price / Book	1.88	6.10	12.91	6.24
Net Income	-$39.65M	$148.67M	$3.45B	$347.60M
7 Day Performance	8.92%	1.84%	1.12%	1.07%
1 Month Performance	28.83%	4.56%	1.79%	1.03%
1 Year Performance	29.64%	8.67%	67.69%	20.77%

OrthoPediatrics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KIDS OrthoPediatrics	2.1881 of 5 stars	$24.80 -0.8%	$25.89 +4.4%	+24.5%	$653.01M	$236.35M	N/A	200
BFLY Butterfly Network	0.9461 of 5 stars	$8.89 +8.1%	$5.56 -37.4%	+529.5%	$2.09B	$97.61M	N/A	460	Insider Trade Gap Down
ATRC AtriCure	4.1914 of 5 stars	$39.00 +0.7%	$48.50 +24.4%	+18.5%	$1.97B	$534.53M	185.72	1,300
ENOV Enovis	3.6306 of 5 stars	$30.76 -2.1%	$41.86 +36.1%	-13.3%	$1.81B	$2.25B	N/A	7,802
NVCR NovoCure	3.6195 of 5 stars	$16.27 +6.2%	$21.20 +30.3%	+49.2%	$1.78B	$655.35M	N/A	1,605	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KIDS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Competitors

KIDS vs. BFLY, ATRC, ENOV, NVCR, and OMCL

How does OrthoPediatrics compare to Butterfly Network?

Summary

How does OrthoPediatrics compare to AtriCure?

Summary

How does OrthoPediatrics compare to Enovis?

Summary

How does OrthoPediatrics compare to NovoCure?

Summary

How does OrthoPediatrics compare to Omnicell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Competitors

KIDS vs. BFLY, ATRC, ENOV, NVCR, and OMCL

How does OrthoPediatrics compare to Butterfly Network?

Do analysts rate KIDS or BFLY?

Do institutionals and insiders believe in KIDS or BFLY?

Does the media favor KIDS or BFLY?

Which has more volatility and risk, KIDS or BFLY?

Which has higher earnings and valuation, KIDS or BFLY?

Is KIDS or BFLY more profitable?

Summary

How does OrthoPediatrics compare to AtriCure?

Do analysts recommend ATRC or KIDS?

Do institutionals & insiders believe in ATRC or KIDS?

Which has more risk and volatility, ATRC or KIDS?

Does the media prefer ATRC or KIDS?

Is ATRC or KIDS more profitable?

Which has higher earnings & valuation, ATRC or KIDS?

Summary

How does OrthoPediatrics compare to Enovis?

Is KIDS or ENOV more profitable?

Do analysts rate KIDS or ENOV?

Which has stronger earnings & valuation, KIDS or ENOV?

Do insiders & institutionals believe in KIDS or ENOV?

Which has more risk and volatility, KIDS or ENOV?

Does the media favor KIDS or ENOV?

Summary

How does OrthoPediatrics compare to NovoCure?

Does the media favor KIDS or NVCR?

Do insiders and institutionals believe in KIDS or NVCR?

Which has stronger valuation and earnings, KIDS or NVCR?

Is KIDS or NVCR more profitable?

Which has more volatility & risk, KIDS or NVCR?

Do analysts prefer KIDS or NVCR?

Summary

How does OrthoPediatrics compare to Omnicell?

Is OMCL or KIDS more profitable?

Do analysts prefer OMCL or KIDS?

Does the media prefer OMCL or KIDS?

Do insiders & institutionals have more ownership in OMCL or KIDS?

Which has more risk & volatility, OMCL or KIDS?

Which has stronger earnings and valuation, OMCL or KIDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools